Skip to main content
David Lynch, MD, Neurology, Philadelphia, PA

DavidRLynchMD

Neurology Philadelphia, PA

Professor, Neurology, Perelman School of Medicine

Dr. Lynch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lynch's full profile

Already have an account?

  • Office

    3401 Civic Center Blvd
    Childrens Hospital of Philadelphia Neurology
    Philadelphia, PA 19104
    Phone+1 215-590-1719
    Fax+1 215-590-1771

Education & Training

  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1988

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • MD State Medical License
    MD State Medical License 2022 - 2024
  • NY State Medical License
    NY State Medical License 2021 - 2024
  • PA State Medical License
    PA State Medical License 1990 - 2024
  • VA State Medical License
    VA State Medical License 2021 - 2024
  • NC State Medical License
    NC State Medical License 2020 - 2022
  • OH State Medical License
    OH State Medical License 1990 - 2014
  • American Board of Psychiatry and Neurology Neurology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
    Vigil Neuroscience Announces First Subject Enrolled in a Natural History Study of Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)September 15th, 2021
  • Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
    Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development ProgramsAugust 9th, 2021
  • Could Statins Ease Deadly Heart Condition in Friedreich’s Ataxia?
    Could Statins Ease Deadly Heart Condition in Friedreich’s Ataxia?April 17th, 2018

Grant Support

  • Nicotinic-Glutamatergic Interactions In Axonal DevelopmentNational Institute Of Neurological Disorders And Stroke2011
  • Regulation Of NMDA Receptors In Excitotoxicity By Calpain And FYNNational Institute Of Neurological Disorders And Stroke2008–2011
  • Defining The Epitope In Antinmda Receptor EncephalitisNational Institute Of Neurological Disorders And Stroke2009–2010
  • Regulation Of NMDA Receptors In Excitotoxicity By Calpain And FYNNational Institute Of Neurological Disorders And Stroke2007
  • Calpain Mediated Cleavage Of NR2 In ExcitotoxicityNational Institute Of Neurological Disorders And Stroke2004–2006
  • Calpain Mediated Cleavage Of NR2 In ExcitotoxicityNational Institute Of Neurological Disorders And Stroke2003
  • NMDA Receptors, Protein Kinase C, And ExcitotoxicityNational Institute Of Neurological Disorders And Stroke1999–2002
  • PCP And The NMDA ReceptorNational Institute On Drug Abuse1996–1999
  • Biochemical Approach To NMDA Receptors &ExcitotoxicityNational Institute Of Neurological Disorders And Stroke1995–1999
  • NMDA Receptors--Biochemical Definition And Pharmacological CharacterizationEunice Kennedy Shriver National Institute Of Child Health &Human Development1995–1999